Suppr超能文献

相似文献

1
Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates.
J Child Orthop. 2012 Mar;6(1):21-7. doi: 10.1007/s11832-011-0380-0. Epub 2012 Jan 17.
2
Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
J Bone Miner Res. 2017 May;32(5):1034-1039. doi: 10.1002/jbmr.3071. Epub 2017 Feb 28.
3
Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1333-1339. doi: 10.1210/jc.2016-3745.
4
Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series.
Osteoporos Int. 2019 Feb;30(2):513-517. doi: 10.1007/s00198-018-4769-1. Epub 2018 Nov 17.
5
Reducing fracture incidence in children with osteogenesis imperfecta: contribution of orthotics to bisphosphonates treatment.
Disabil Rehabil. 2024 Apr;46(7):1416-1421. doi: 10.1080/09638288.2023.2198259. Epub 2023 Apr 17.
6
Bisphosphonate therapy for osteogenesis imperfecta.
Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4.
7
Bisphosphonate therapy for osteogenesis imperfecta.
Cochrane Database Syst Rev. 2014 Jul 23(7):CD005088. doi: 10.1002/14651858.CD005088.pub3.

引用本文的文献

1
The administration of exogenous HSP47 as a collagen-specific therapeutic approach.
JCI Insight. 2025 Feb 6;10(6):e181570. doi: 10.1172/jci.insight.181570.
2
Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.
Front Endocrinol (Lausanne). 2022 Sep 26;13:901925. doi: 10.3389/fendo.2022.901925. eCollection 2022.
3
Inhibition of TGF-β Increases Bone Volume and Strength in a Mouse Model of Osteogenesis Imperfecta.
JBMR Plus. 2021 Aug 3;5(9):e10530. doi: 10.1002/jbm4.10530. eCollection 2021 Sep.
4
5
Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.
Bone. 2019 Oct;127:199-206. doi: 10.1016/j.bone.2019.06.018. Epub 2019 Jun 21.
6
Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.
JBMR Plus. 2018 Jan 3;2(1):1-11. doi: 10.1002/jbm4.10024. eCollection 2018 Jan.
7
Incidence and treatment of femur fractures in adults with osteogenesis imperfecta: an analysis of an expert clinic of 216 patients.
Eur J Trauma Emerg Surg. 2020 Feb;46(1):165-171. doi: 10.1007/s00068-018-1005-9. Epub 2018 Sep 22.
8
Developments in rare bone diseases and mineral disorders.
Ther Adv Chronic Dis. 2018 Jan;9(1):51-60. doi: 10.1177/2040622317739538. Epub 2017 Nov 24.
9
Femoral neck fractures in osteogenesis imperfecta treated with bisphosphonates.
J Child Orthop. 2017 Jun 1;11(3):191-194. doi: 10.1302/1863-2548.11.160212.

本文引用的文献

1
Bisphosphonate therapy for osteogenesis imperfecta.
Cochrane Database Syst Rev. 2014 Jul 23(7):CD005088. doi: 10.1002/14651858.CD005088.pub3.
2
Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?
J Bone Joint Surg Br. 2011 Oct;93(10):1289-95. doi: 10.1302/0301-620X.93B10.26924.
4
A rational approach to management of alendronate-related subtrochanteric fractures.
J Bone Joint Surg Br. 2010 May;92(5):679-86. doi: 10.1302/0301-620X.92B5.22941.
6
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.
7
Long-term use of bisphosphonates in osteoporosis.
J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19.
9
A fracture risk assessment model of the femur in children with osteogenesis imperfecta (OI) during gait.
Med Eng Phys. 2009 Nov;31(9):1043-8. doi: 10.1016/j.medengphy.2009.06.010. Epub 2009 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验